Almac Clinical Technologies has announced the launch of a standardized, operationally-proven integration between its Interactive Response Technology platform - IXRS® 3 and Exostar’s Identity and Access Management Platform.
Standardizes integration and frictionless identity management integration for BioPharmaSouderton, PA, USA, 12 Dec 2019 – Almac Clinical Technologies, a member of the Almac Group, has today announced the launch of a standardized, operationally-proven integration between its Interactive Response Technology (IRT) platform - IXRS® 3 and Exostar’s Identity and Access Management Platform.
The two global companies first announced a pilot partnership in December 2016 to demonstrate a proof-of-concept for eClinical application users to benefit from Exostar’s industry-leading Single Sign-On (SSO) expediency and enhanced security.
This latest technological advance will enable users of Almac Clinical Technologies’ Interactive Response Technology (IRT) to harness Exostar’s industry-leading credentialing, federation, and web-based Single Sign-On (SSO) capabilities to seamlessly and securely log in to Almac’s IXRS® 3 with credentials provided to each user by any member of the Exostar Life Sciences Community – which includes Trial Sponsors, Contract Research Organizations (CROs), cloud application providers, and others. Half of the world’s 20 largest pharmaceutical companies and nearly 15,000 industry organizations actively participate in the Exostar Life Sciences Community.
In addition, the collaboration with Exostar allows Almac to further its mission of enhancing the patient experience. The upgraded identity management capabilities within IXRS® 3 created as a result of the integration eliminate a major burden on trial sites, and enable them to focus more time and energy on patient care.
Valarie Higgins, President and Managing Director, Almac Clinical Technologies commented: “I’m delighted to further expand the capabilities of the IXRS® 3 solution and help broaden the ecosystem created by Exostar’s identity management platform and Transcelerate’s Shared investigator platform. These enhancements help to further our mission of creating a better IRT experience by reducing the burden on investigators and their teams, and leaving them with more time to spend with their patients.”
Kenny Kong, Director of Life Sciences & Health IT for Exostar added: “The clinical trials experience is going digital with the eClinical revolution, making ease of secure access a top priority. Sites need on-demand access to sponsor applications without the burden and vulnerability of juggling unique logins and credentials for each sponsor. Sponsors must quickly activate their sites and empower them with the tools they need to advance their studies. All parties require an identity and access management experience that’s simple, straightforward, and secure. The Almac/Exostar integration enables IXRS® 3 users to realize those benefits.”
If you’re interested in learning more about this collaboration and how it can support your clinical trial, Almac Clinical Technologies and Exostar will be co-presenting at the SCOPE Summit for Clinical Ops Executives from 18th to 21 February in Orlando, Fl. –find out more here.
ENDS
About Almac Group
‘Partnering to Advance Human Health’
The Almac Group is an established contract development and manufacturing organisation providing an extensive range of integrated services across the drug development lifecycle to the pharmaceutical and biotech sectors globally. Its innovative services range from R&D, biomarker discovery development and commercialisation, API manufacture, formulation development, clinical trial supply, IRT (IVRS/IWRS) through to commercial-scale manufacture.
The international company is a privately owned organisation which has grown organically over the past five decades now employing over 5,600 highly skilled personnel across 17 facilities including Europe, the US and Asia.
The company has a global reputation for excellence built over 50 years of client service, delivering expertise right across the drug development lifecycle and offering a tailored solution to each of our clients. To keep up to date with our latest news, follow us on Twitter and LinkedIn or visit almacgroup.com.
About Exostar
The leader in trusted, secure business collaboration in aerospace and defense, life sciences, and healthcare.
Exostar’s cloud-based platforms create exclusive communities within highly-regulated industries where organizations securely collaborate, share information, and operate compliantly. Within these communities, we build trust. More than 135,000 Aerospace and Defense organizations and agencies in over 150 countries trust Exostar to strengthen security, reduce expenditures, raise productivity, and help them achieve their missions. Ten of the top twenty global biopharmaceutical companies rely on Exostar to help them speed new medicines and therapies to market. Exostar is a Gartner Cool Vendor. For more information, please visit www.exostar.com.
